Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0198)
Name |
20-Hydroxyeicosatetraenoic acid
|
||||
---|---|---|---|---|---|
Synonyms |
20-Hete; 79551-86-3; 20-Hydroxyeicosatetraenoic acid; 20-Hydroxy arachidonic acid; 20-Hydroxyarachidonic acid; (5Z,8Z,11Z,14Z)-20-Hydroxyicosa-5,8,11,14-tetraenoic acid; 20-hydroxy-5,8,11,14-eicosatetraenoic acid; 20-Hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoic acid; 20-Hydroxyicosatetraenoic acid; 20-Hydroxyeicosatetraeonic acid; 20-hydroxy-5Z,8Z,11Z,14Z-eicosatetraenoic acid; 5,8,11,14-Eicosatetraenoicacid, 20-hydroxy-, (5Z,8Z,11Z,14Z)-; 20-Hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate; (5Z,8Z,11Z,14Z)-20-Hydroxyicosa-5,8,11,14-tetraenoate; 20-Hydroxyicosatetraenoate; SCHEMBL505713; GTPL4103; CHEMBL4085458; CHEBI:34306; 5,8,11,14-Eicosatetraenoic acid, 20-hydroxy-, (all-Z)-; DTXSID601009895; LMFA03060009; CS-1451; HY-15598; 20-hydroxy-5,8,11,14-eicosatetraenoate; 20-hydroxy-5Z,8Z,11Z,14Z-eicosatetraenoate; SR-01000946981; (all-Z)-20-hydroxy-5,8,11,14-Eicosatetraenoate; SR-01000946981-1; Q21099666; (all-Z)-20-hydroxy-5,8,11,14-Eicosatetraenoic acid; 20-hydroxy-5(Z),8(Z),11(Z),14(Z)-eicosatetraenoic acid; 20-Hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoic acid, ~100 mug/mL in ethanol, >=90% (HPLC)
Click to Show/Hide
|
||||
Status |
Investigative
|
||||
Drug Type |
Small molecular drug
|
||||
Structure |
![]() |
||||
Formula |
C20H32O3
|
||||
IUPAC Name |
(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoic acid
|
||||
Canonical SMILES |
C(CCC=CCC=CCC=CCC=CCCCC(=O)O)CCO
|
||||
InChI |
InChI=1S/C20H32O3/c21-19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18-20(22)23/h1,3-4,6-7,9-10,12,21H,2,5,8,11,13-19H2,(H,22,23)/b3-1-,6-4-,9-7-,12-10-
|
||||
InChIKey |
NNDIXBJHNLFJJP-DTLRTWKJSA-N
|
||||
PubChem CID | |||||
TTD Drug ID |
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
In total 1 item(s) under this Target | |||||
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Intracerebral hemorrhage | ICD-11: 8B00 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | mOHSCs (Mouse organotypic hippocampal slice cultures) | ||||
In Vivo Model |
Adult male C57BL/6J mice were obtained from the Jackson Laboratory (Bar Harbor, ME USA). Mice at 10-12 weeks of age were anesthetized by 1-3% isoflurane inhalation and ventilated with oxygen-enriched air (20% O2:80% air). The right striatum of mice was injected with 0.5 ul of 0.075 U collagenase VII-S (MilliporeSigma, St. Louis, MO, USA) at 0.1 ul per minute. Injections were administered at 0.5 mm anterior and 2.2 mm lateral of the bregma, and 3.0 mm in depth, as previously described. Sham-operated mice received the same treatment, including needle insertion, but were not injected with collagenase. Mice that died before the end of the surgery or shortly thereafter were excluded.
Click to Show/Hide
|
||||
Response regulation | 20-hydroxyeicosatetraenoic acid induces ferroptosis in OHSCs, and inhibition of 20-HETE synthesis improves Intracerebral hemorrhage (ICH) outcome and attenuates markers of ferroptosis, such as mobile iron, lipid peroxidation, and decreased GPX4. | ||||